NCCN 2^nd Annual Congress: Hematologic Malignancies – Myelodysplastic Syndromes: Treatment by Risk Groups

Download Podcast

Listen to MP3

Podcast Evaluation

A presentation from the NCCN 2^nd Annual Congress: Hematologic Malignancies™ held September 14-15, 2007, in New York, New York

Presenter

Harry Erba, MD, PhD
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan

Faculty Disclosure Statement

Dr. Erba has disclosed that he has financial interests, arrangements, or affiliations with the manufacturer of products and devices to be discussed in his presentation or who may financially support the educational activity.  He has served as a consultant for Genzyme Corporation and an investigator for Cephalon, Inc.; Kanisa Pharmaceuticals, Inc.; and Xanthus Pharmaceuticals, Inc.  He has also served as a speaker for Celgene Corporation; Cephalon, Inc.; Genzyme Corporation; Novartis Pharmaceuticals Corporation; Pharmion Corporation; and Wyeth.

Dr. Erba has indicated that his presentation will include discussion of investigational or unlabeled uses of a product.

Program Overview

Treatment of hematologic malignancies is increasingly complex.  Issues relating to pathology, transplantation, and various new therapies require oncologists and hematologists to stay abreast of new advances.  In addition, targeted therapies and oral treatments bring new benefits to patients. This program will focus on the new approaches that have been incorporated into the management of myelodysplastic syndromes (MDS) based on risk group.

Educational Objectives

Following this activity, participants should be able to:

• List the appropriate pathology techniques for diagnosis and prognostic modeling for patients with MDS
• Identify the available therapeutic options for MDS
• Describe the clinically relevant subtypes of MDS and risk assessment with respect to their roles in selecting therapy

Intended Audience

This educational activity is designed to meet the needs of physicians, nurses, and other clinical professionals who manage patients with cancer.

Activity Instructions

Continuing education credit will be awarded to participants who listen to the presentation and complete the evaluation.  Participants should review the learning objectives and faculty disclosure statements prior to listening to a presentation in its entirety.  You must be connected to the Internet in order to review and complete the evaluation form.  A statement of credit will be electronically generated once you complete the evaluation form.  To receive credit, this activity must be completed no later than November 1, 2008.  There is no fee for participating in this activity.

Download Podcast

Listen to MP3

Podcast Evaluation

Accreditation Information

Physicians

The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

NCCN designates this educational activity for a maximum of 0.5 AMA PRA Category 1
Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses

This activity is approved for 0.5 contact hours.  National Comprehensive Cancer Network is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation or PA Nurses approval or endorsement of any product.

Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.

Release date:  November 1, 2007
Expiration date:  November 1, 2008